Euroopa Liit -
eesti -
EMA (European Medicines Agency)
adempas
bayer ag - riociguat - hüpertensioon, kopsuvähk - antihüpertensiivsed ravimid kopsuarteri hüpertensioonile - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efektiivsust on näidatud pah elanikkonnale, sh aetiologies idiopaatiline või pärilik pah või pah seotud sidekoe haigus. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
Eesti -
eesti -
Ravimiamet
itraconazol actavis kõvakapsel
teva b.v. - itrakonasool - kõvakapsel - 100mg 28tk; 100mg 15tk; 100mg 30tk; 100mg 4tk; 100mg 18tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
zelboraf
roche registration gmbh - vemurafeniib - melanoom - antineoplastilised ained - vemurafeniib on näidustatud monoteraapiana braf-v600-mutatsiooni-positiivse retseptorita või metastaatilise melanoomiga täiskasvanud patsientide raviks.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
tagrisso
astrazeneca ab - osimertinib mesilate - kartsinoom, mitteväikerakk-kopsu - muud antineoplastilised ained, protein kinase inhibiitorid - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
Eesti -
eesti -
Ravimiamet
onkotrone infusioonilahuse kontsentraat
oÜ baxter estonia - mitoksantroon - infusioonilahuse kontsentraat - 2mg 1ml 5ml 1tk; 2mg 1ml 10ml 1tk; 2mg 1ml 15ml 1tk; 2mg 1ml 12.5ml 1tk
Eesti -
eesti -
Ravimiamet
cladosol 100mg kõvakapsel
stada arzneimittel ag - itrakonasool - kõvakapsel - 100mg 4tk; 100mg 14tk; 100mg 50tk; 100mg 6tk; 100mg 15tk; 100mg 30tk; 100mg 18tk; 100mg 28tk; 100mg 8tk; 100mg 84tk
Eesti -
eesti -
Ravimiamet
mitoxantrone accord 2 mg/ml infusioonilahuse kontsentraat
accord healthcare b.v. - mitoksantroon - infusioonilahuse kontsentraat - 2mg 1ml 15ml 1tk; 2mg 1ml 10ml 1tk; 2mg 1ml 15ml 5tk; 2mg 1ml 5ml 1tk; 2mg 1ml 5ml 5tk; 2mg 1ml 10ml 10tk; 2mg 1ml 15ml 10tk
Eesti -
eesti -
Ravimiamet
marevan forte tablett
orion corporation - varfariin - tablett - 5mg 100tk